Abstract
The European Commission has approved durvalumab (Imfinzi®; AstraZeneca)* and olaparib (Lynparza®; AstraZeneca)**, the first immunotherapy and PARP inhibitor combination, for the treatment for certain patients with primary advanced or recurrent endometrial cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
